Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8785068 | 0.98 | MAPT (0.54) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL68851 | 0.90 | CYP4Z1 (0.62) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL11135790 | 0.89 | CYP4Z1 (0.46) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL5725282 | 0.86 | LOXL2 (0.49) | CYP4Z1SMN1; SMN2LOXL2ALDH1A1MEN1 | |
| SCHEMBL10461745 | 0.85 | CYP4F2 (0.53) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL85523 | 0.85 | PPID (0.58) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| Hydrochloric Acid SCHEMBL5725276 | 0.84 | LOXL2 (0.47) | CYP4Z1MAPTSMN1; SMN2LOXL2ALDH1A1 | |
| SCHEMBL6057577 | 0.84 | CYP4F2 (0.59) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL68930 | 0.84 | CYP4Z1 (0.57) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL10299459 | 0.84 | CYP4Z1 (0.57) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115836054-A | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2018229139-A1 | NOVEL COMPOUNDS FOR USE IN CANCER | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2018-12-20 | — | — | WO | disclosed |
| CN-102348682-B | 1,1,1-trifluoro-2-hydroxypropyl compounds | HOFFMANN LA ROCHE | 2014-07-30 | — | — | CN | disclosed |
| EP-2411361-B1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-8138189-B2 | Substituted benzene compounds as modulators of the glucocorticoid receptor | HOFFMAN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| CN-102348682-A | 1,1,1-trifluoro-2-hydroxypropyl compounds | HOFFMANN LA ROCHE | 2012-02-08 | — | — | CN | disclosed |
| EP-2411361-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010108902-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| CN-100371329-C | Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases | AVENTIS PHARMA GMBH (DE) | 2008-02-27 | — | — | CN | disclosed |
| CN-1835953-A | 4-Cycloalkylaminopyrazolopyrimidine NMDA/NR2B antagonists | MERCK & CO INC (US) | 2006-09-20 | — | — | CN | disclosed |
| CN-1714083-A | Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases | AVENTIS PHARMA GMBH (DE) | 2005-12-28 | — | — | CN | disclosed |
| CN-1656091-A | Tetrahydropyran derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | CN | disclosed |
| CN-1620451-A | Diphenylmethyl derivative | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-05-25 | — | — | CN | disclosed |
| WO-2004018448-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-0237678-B1 | TRYPTAMINE DERIVATIVES, THEIR SYNTHESIS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 1991-04-03 | — | — | EP | disclosed |
| US-4870096-A | MIGRAINE | GLAXO GROUP LIMITED (GB) | 1989-09-26 | — | — | US | disclosed |
| EP-0237678-A1 | Tryptamine derivatives, their synthesis and their use in pharmaceutical compositions | GLAXO GROUP LIMITED (GB) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, CRHR1 | CYP4Z1 451/4885MAPT 2644/4885LMNA 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.